Compare Goldman Sachs Group Inc (GS) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Natera Inc. Common Stock — how do they compare? Goldman Sachs Group Inc trades at $882.79 (market cap $259.70B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Goldman Sachs Group Inc is far larger — about 4.6× Natera Inc. Common Stock's market cap, and Goldman Sachs Group Inc pays a 2.24% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 100 Days and Natera Inc. Common Stock for 0 Days on average.
| GS | NTRA | |
|---|---|---|
Market Cap | $259.70B | $57.03B |
Volume | 4,939,526 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $1.15K | $425.64 |
52-Week Low | $744.60 | $179.42 |
Typical Hold Time | 100 Days | 0 Days |
Enterprise Value | $263.03B | $56.18B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $893.95, down 0.15% with bearish technical signals but strong fundamental performance. The stock shows consistent earnings beats with Q3 2026 EPS of $17.01 exceeding expectations by 32%. Revenue growth accelerated to $58.28B in 2025 with net income margin improving to 29.46%. Recent news highlights the company's focus on expanding its $70B revenue base and AI initiatives.
GS presents a compelling value case with a P/E of 13.77 below industry averages, supported by 40% analyst buy ratings and a $1,130 consensus price target. However, negative operating cash flow trends and bearish technical indicators suggest near-term volatility. The dividend yield of approximately 0.56% provides income support while the company executes its growth strategy.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
